US-based biotechnology firm Halozyme Therapeutics has initiated a Phase Ib/II clinical trial of PEGPH20 and atezolizumab (Tecentriq) combination to treat metastatic pancreatic ductal adenocarcinoma.

PEGPH20 is currently being developed as a form of the firm’s recombinant human hyaluronidase and is an enzyme designed to temporarily degrade hyaluronan (HA) component of tumour microenvironment, while atezolizumab is Genentech’s anti-PDL1 cancer immunotherapy.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The open-label, multi-centre, randomised Phase Ib/II trial is part of a clinical collaboration agreement signed last year by the firms to assess the combination in approximately eight types of tumours.

The trial will compare the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of the combination therapy with conventional chemotherapy treatments.

"We are pleased to provide PEGPH20 in this collaboration study, to evaluate and potentially advance new treatment options for patients with pancreatic cancer, one of the hardest to treat cancers."

Halozyme Therapeutics president and CEO Dr Helen Torley said: "This clinical trial expands the study of PEGPH20 in pancreatic cancer, evaluating previously treated pancreas cancer patients and combining PEGPH20 with an anti-PDL1 monoclonal antibody for the first time.

See Also:

"We are pleased to provide PEGPH20 in this collaboration study, to evaluate and potentially advance new treatment options for patients with pancreatic cancer, one of the hardest to treat cancers."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Planned to be performed in multiple countries, the Phase Ib/II trial will be funded by Genentech.

PEGPH20 is currently being developed to treat metastatic pancreatic cancer, gastric cancer, non-small-cell lung cancer and metastatic breast cancer, with the potential to be a combination therapy for various other cancers.

The US Food and Drug Administration also granted PEGPH20 with orphan drug designation for pancreatic cancer and fast-track designation in combination with gemcitabine and nab-paclitaxel for metastatic pancreatic cancer.